CASGEVY — Product revenues, net
Vertex Pharmaceuticals CASGEVY — Product revenues, net decreased by 44.4% to $16.90M in Q3 2025 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful commercial rollout, patient access, and market adoption of the gene-editing therapy, while a decrease may signal competitive pressure, reimbursement challenges, or slower-than-expected patient uptake.
Detailed definition
This metric represents the total net revenue generated from the sale of a specific gene-editing therapy product after ac...
Peer comparison
Comparable to revenue metrics for specialized orphan drugs or gene-editing therapies at other biotechnology firms, where early-stage commercialization often shows high growth rates as patient access expands.
vrtx_segment_casgevy_product_revenues_netHistorical Data
| Q2 '24 | Q3 '24 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|
| Value | $0.00 | $2.00M | $30.40M | $16.90M |
| QoQ Change | — | — | >999% | -44.4% |
| YoY Change | — | — | — | +745.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's casgevy — product revenues, net?
- Vertex Pharmaceuticals (VRTX) reported casgevy — product revenues, net of $16.90M in Q3 2025.
- What does casgevy — product revenues, net mean?
- The total net sales revenue generated from the company's gene-editing therapy product.